OrthoPediatrics Corp. (KIDS)
NASDAQ: KIDS · Real-Time Price · USD
31.41
-0.09 (-0.29%)
Nov 17, 2026, 4:00 PM EST - Market closed
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Q3 revenue grew 19% across businesses, with record EBITDA and positive free cash flow; management expects at least $6M Q4 FCF and reiterated its 2026 break-even FCF goal. Staggered product launches and OPSB expansion support a multi-year growth runway.

Rick Wise
Managing Director, Stifel

Hello again. Welcome to our next presentation. My name is Rick Wise. I am delighted to welcome Dave Bailey, President and Chief Executive Officer of OrthoPediatrics, stock symbol KIDS, and Joe Hauser, to Dave's left, President of the Trauma, Deformity Correction, and OPSB business. OPSB, the fastest-growing division at OrthoPediatrics. Very impressive. I will say, these last three quarters, just 20% plus, Joe. Good job. With that.

Oh, then there's the CEO.

Dave, seriously, I want to start today both in focus, both near term and longer term. Let us just start off with your truly excellent third quarter results, and not just the setup for the fourth quarter, but as a staging point for 2027. The quarter was excellent, better than expected sales growth, positive adjusted EBITDA, and free cash flow, very solid directionally. All key goals for you and the team.

Am I overstating it, or was that your reaction as well?

Dave Bailey
President and CEO, OrthoPediatrics

No, I think the quarter was fantastic. The quarter before was very, very strong as well, particularly if you take the 7D and some of the headwinds that we have had in Brazil. I think the organic side of that business, minus some of those one-times, grew really, really rapidly in the second quarter. The year, now we come more towards the close, but if you look at how the company has performed across the entirety of the year, it performed really well. I think what I am most pleased with is it is very balanced, and Q3 was extremely balanced.

Rick Wise
Managing Director, Stifel

Yeah.

Dave Bailey
President and CEO, OrthoPediatrics

Obviously, 19% growth, very, very strong, but it was not from any big one-time sales. It was across all the businesses. Trauma and Deformity performed really well. Scoliosis performed really well. The international business performed really well, and obviously, the rock star here, Joe, in the OPSB franchise growing north of 20%. All the businesses performing really well. The EBITDA was a record for us. We still have some work to do to continue to see that EBITDA growth, and continue to get leverage, and then to generate positive free cash flow in Q3. As you know, we generated for the first time in Q4 last year, $10 million in positive FCF, and had drastically reduced our cash usage from 2024 to 2025, committed to 2026 break-even from an FCF standpoint.

I think given that we did $10 million in fourth quarter of last year, we're a good setup here to generate at least $6 million in Q4 and get to our goal that we've stated now for the last few years, and been quite methodical about that. I'm very pleased to see the way the business has grown, and I think it's partially because of the new products, but also just really strong use of our legacy products and pull-through from a lot of those legacy products because of some of the Super Cycle products. I think it sets us up really well for 2027 and beyond as well.

Rick Wise
Managing Director, Stifel

Just not to dwell on the fourth quarter, but it feels like the business obviously is strong, but momentum is positive heading into the fourth quarter. I know that not like every medical device company, maybe third quarter is often a little stronger period for a variety of reasons than the fourth. But my numbers to get to, like in rough numbers, $69 million in the fourth quarter, that's a 5% sequential deceleration. Is that the right way to think about it? Are you feeling I don't know how to ask about it, but the business itself, the tone, the new product uptake, things are going along pretty smoothly.

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, I mean, overall, if you just look at the seasonality of our business, Q4 is generally weaker than Q3 and weaker than Q2. Kids are out of school in the summer, so they're getting braces fitted, they're having scoliosis procedures. A lot of our high ASP, most complicated procedures occur during the summer months. We had a very, very robust summer. So it's rational to think that the seasonality would follow suit like it's followed for the last several years. Some of that seasonality gets offset as the OPSB business grows because of deductibles and people trying to get their bracing taken care of into the fourth quarter. But we still think seasonality is a rational way to forecast the business. We're going to continue to be relatively conservative in our guide.

Not giving guide, I know you'll ask, but not giving guide for 2027, but I think you can expect us to hew to what's worked here and not get in front of ourselves. We also have a 7D comp in Q4, and as you know, we've tried to eliminate most of the 7D sales out of our guide. We can't exactly determine when those units are going to come through. We did have a pretty strong Q4 last year.

Of 7D, and we also continue to limit set sales to partners in Latin America because it is balancing. We want to get our AR balance up there, and it is a focus on profitable sales that are contributing to positive free cash as opposed to potentially slowing us down in terms of our goal of generating positive free cash.

Rick Wise
Managing Director, Stifel

You have signaled previously expectations for OUS growth to exceed the U.S. in coming years after some of the moves you have made in recent years, and yet the third quarter U.S. was faster. Fourth quarter, I mean, I realize there are some headwinds, or cross-currents, if you will, but with the product Super Cycle uptake initially so strong, and we are going to talk more about it in a second, is that the right way to think about the growth outlook now?

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, I think we are under-penetrated internationally. Obviously, we started in the U.S. much earlier. We have more of our focus in the U.S., and we have some headwinds. Certainly with some of our stocking distributors, we are just not offering the kind of payment terms that we had in the past.

Rick Wise
Managing Director, Stifel

Right.

Dave Bailey
President and CEO, OrthoPediatrics

We still have headwinds, particularly in Brazil, particularly in LATAM. We are facing some tough comps where we have sold sets in the past. But I think if you look at the underlying growth, like just the replenishment usage of our products outside of the United States, the replenishment usage overall is probably growing much faster if you kind of take out some of the one-time sales and headwinds.

Rick Wise
Managing Director, Stifel

Right.

Dave Bailey
President and CEO, OrthoPediatrics

Super cycle really not contemplated outside of the U.S. yet. We haven't started selling any of these products and really aren't projecting to sell a lot of these products in 2027. But the EU MDR approvals have become very, very significant for us, and we're really in the early innings of starting to launch products in Europe that we have been launched here in the United States several years ago. I would point out that we've had very strong international scoliosis revenue, and particularly in Europe. Some of that, again, has been offset by set sales in Brazil. Some of these set sales are $1 million. So when you look at the growth rate of our scoliosis franchise, high mid-teens, then offset by, in some cases, $1 million orders in those quarters, the underlying strength of scoliosis has been very strong.

If you really parse out what's happening in Europe, it's a small business, but it's growing very rapidly, and that has been impacted by being able to get more of our scoliosis fusion products available to surgeons in countries like Ireland, the U.K., and we're very early in the growth story, I think, for the scoliosis business in Europe. So, it may be more similar to maybe more parity between the U.S. and OUS business going forward, but generally speaking, we're under-penetrated. We have a lot of growth opportunities in international and still feel very bullish about being able to grow the way we've grown in the past.

Rick Wise
Managing Director, Stifel

Just reflecting on the company, just now bigger picture and looking ahead, before we talk about the Super Cycle again, just since the IPO, you've just steadily built a broader, deeper, more diversified pediatric orthopedics platform. Just at a high level, how do we think about the growth runway from here? Just at a high level, is it deeper penetration into existing hospitals? Is it opening new hospitals? You talked about the international expansion, or is the major opportunity growing the OPSB bracing clinic business and pulling through everything? How are you pushing the big levers and buttons here?

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, so it's a little bit of all those things, which I think is good. We don't have one specific part of our strategy that is outsized over all others. It is mainly, though, getting deeper penetration in existing children's hospitals. There's not that many children's hospitals where we could say we have 100% of the market share, although through contracting, which I know you like to talk about, the contracting, single vendor, dual vendor contracts that are happening at a more frequent pace now. I think that there's just a lot of growth opportunities for us. We're in every children's hospital in the United States and in Canada.

Doesn't mean every surgeon is using every one of our products. When we deliver more kind of what I would call N of one solutions, like 3P Hip, for example, some of the Pega products, VerteGlide, it's giving us leverage to pull through the more commoditized products. When we also see companies that are exiting the space, particularly on the Trauma and Deformity side, it makes some of our legacy products more valuable and gives us leverage in those conversations. I think it's more about us continuing to get deeper and deeper penetration. I mean, you've probably heard us say this, but our aspiration long term is to help a million children a year. Our goal this year is to help about 175,000.

If you put that into context for where we think how we can grow the business, we're still in the early growth phases of this business, even though we've been public nine years. We think that over the course of the next several years, the opportunity to truly take a completely dominant position in the subspecialty of pediatric orthopedics is well within our charge, and I see no resistance to us being able to do that over the course of the next several years.

Rick Wise
Managing Director, Stifel

I agree, for what it's worth. Just again, as we start to think about the Super Cycle impact, just at a high level, I mean, for those less familiar with all the symptoms, I think even I get overwhelmed with the incredible number of products and what they do and what they could mean. Is it new products replacing older products, already existing products? Are you opening up new sub-segments, part of the whole that you weren't in before? How do we think about it at a high level?

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, I'll turn this over to Joe, but I think first, there is very little replacement in this. There's a few products that I think overlap, but primarily it's expanding the potential indications surgeons can use our products on. There's a number of procedures that frankly just can't happen in pediatric orthopedics because they don't have the appropriate instrumentation or products, implant products, and certainly on the bracing side, you see a large-scale bastardization of products that aren't made for children. So it's primarily that. There is a little bit of overlap, but it's primarily new, kind of more blue ocean opportunities. I don't know, Joe, if you have other comments.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

No, that's spot on. I think that every system, it's one of the stories of what got us here won't get us there. There's products within each one of these Super Cycle products systems that have a new indication that is blue ocean that might also be partnered with a couple things that we've learned over. We're onto our third generation of some of these systems. There is some things we've learned, and so we've made those adjustments to make the products better that are existing and then offering things that give us some more indications, more case coverage.

Rick Wise
Managing Director, Stifel

Big picture, how much of third quarter, maybe I'll focus on U.S. revenues. How much of third quarter U.S. revenues came from Super Cycle new products? If I ask you the same question in a year ahead or five years ahead, what's that mix going to be from all these products in the pipeline?

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, I would say it's still very early. I mean, it certainly impacted us. Maybe it's a couple points, but I would say the bigger impact was the pull-through of legacy and certainly OPSB growing north of 20%. I think that we're starting to see, really Q3 was the first time we started to see a real impact of the Super Cycle. I think how investors should think about this is that products like 3P Hip, for example, are in their first or second inning in terms of product launch. There's 300 children's hospitals. We have a trivial volume of sets out there.

We're managing growth against producing positive free cash. Next year, 3P Hip will be a huge part of our growth story, right, for Trauma and Deformity , and it'll be maybe in its third or fourth inning, while products like 3P Small Mini become a first inning story.

By the time we get to 2028, 3P Hip will be in its sixth inning, and then Small Mini will be in its third inning, and then there will be 3P Femur that will be in its first inning. That is why we have talked about this as a Cycle, because it is not one product and then we are going to grow this thing exclusively for the next five years. As those products gain momentum, there is another product right behind it. Same thing in our IM Nail portfolio, same thing in our Scoliosis portfolio, and then the work that the team has done on OPSB. There is just a huge volume of really compelling technologies there. I would say when we talk in 2027, 2028, these products will make a bigger percentage of our total sales. They are higher ASP, generally speaking, better margins.

They have better capital utilization metrics impacting our positive free cash flow. So this has a more outsized impact, certainly 2027, 2028, and beyond.

Rick Wise
Managing Director, Stifel

Since you have referenced 3P a couple of times, I think 3P had a full market release in the third quarter, if I am remembering correctly. Should I be asking about reorder trends, or how are you measuring progress there?

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

Yeah. We are way ahead of pace where 3P Hip, where we had originally budgeted for that to be. We are ahead of pace from what we expected since the beginning of the year. Full market release is still relative. To Dave's point, we are still in the early innings. It is not like we have released an extreme number of sets to cover all of the country, but we go out of the limited release to where we have at least added significantly more sets that can get us to different accounts that we were not in today. I think the 3P Hip story is just one of the stories of how 3P is going to serve us over the long haul. So you got definitely some contribution for 3P Hip within Q3.

We are going to see more here within Q4. Going into next year, as more sets get added, we are going to see additional throughout the first half of 2027. Just as that is starting to continue to ramp up, you will start to see how 3P Small Mini goes from a limited release, which it is in right now, into a full market release, where we will add additional sets, and then you will see the early innings of that growth throughout the first half of 2027 into the second half of 2027.

The hardest part is to contextualize that we see there being a long runway of growth, and the value of doing these limited launches, and I know I get asked a lot about, Why limited launch first? It is not just about seeing what is going on with the system with surgeons that are ready to use it. It also allows us to understand the inventory required to actually get to the marketplace.

Gives us a good expectation of what utilization rates we want. When you have multiple different product systems in the Super Cycle, we can decide to launch more of, send more sets out of one that is getting a better utilization rate.

Rick Wise
Managing Director, Stifel

That is right.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

versus others. It is a really nice build, a waterfall, if you may, on how we bring more systems to the market. When you get to the second half of 2027, there will be stuff for 3P Femur and additional systems coming into 2028.

Rick Wise
Managing Director, Stifel

No, I think waterfall or whatever the image should be is a great description. I want to talk about OPSB as a whole in a minute, but maybe since we are focusing, let us take 3P Hip as an example. How does the relationship or the context with OPSB pull through new products like that? I mean, what is special about OPSB being present in a hospital that enables the launch to maybe go faster or better? Talk about that connection.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

For sure. Yeah. I mean, we try to target areas where we are already embedded in a hospital, have a really strong implant presence. So when we look at where we want to be, certainly layers of that start with surgeons that are very familiar with the company, very familiar with our implant products. So when we are having the bracing discussion, it is a pretty easy discussion to transition to why you would want one of our clinics either inside the hospital or nearby or down the street. I think one thing that is interesting relating back to the Super Cycle is some of the products literally cross over between the businesses. So you think about TractorFIX, which is in a limited release now, will go into full market release next year. It is a product that goes with every one of our external fixation ORTHEX system applications.

Every case we do today with ExFix, with the ORTHEX, is an immediate candidate to have a bracing product called TractorFIX. It helps to prevent something that is a really big problem out there, which is flexion contractures. These kids that have frames struggle with how they will walk, and this product helps bring it out. So now you need not only the implant side, but now you can go down to the clinic and be outfitted with one of the braces. I think another good example is TRAXIO, which is part of a halo gravity traction system, which is just the walker or the device that actually holds the child into traction. That is connected to pins and rings that get applied in the OR. We do not have the pins and rings yet. That is going to come out here early on into the next year.

You have what's beyond that, which is some of these children that need fusion surgery after they've been held out in a traction. So you have the product catching the patient earlier in the cycle of treatment, and then ultimately leading to, if they need surgery, our products to be able to offer there. So it's connected pretty well. You can bet that hospitals that use our implant business that are now starting to use our bracing products absolutely want to have a bigger discussion on how they contract with us to get all of our products there.

Rick Wise
Managing Director, Stifel

It really goes both ways. It's interesting. I want to touch on, we've talked about a number of the products, but VerteGlide, the sliding scoliosis rods. On Monday, I think, Dave, you launched the full market release of VerteGlide. You talked about 40 plus hospitals are using it already, maybe. Talk about the case volumes, and how would you quantify the repeat utilization there, if that's the right question? But is VerteGlide also, do you expect it to open up new account wins, et cetera, et cetera?

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, it definitely is. I think that one of the things we've talked about is in the past, where accounts where we've been very strong in Trauma and Deformity , places that are very large, very well-known here on the East Coast, for example, that are top 10 children's hospitals in the United States, oftentimes we've had a really strong presence with those accounts with our Trauma and Deformity business, but less of a presence with our scoliosis fusion business. They may have had a 30-year relationship with Medtronic, for example, or Synthes, DePuy Synthes. Those 30 years were 10 years before we were even a company. So they have very strong relationships, not just with the company, but with the local representatives. Those are things that portion of our business is quite competitive, and it's difficult to break up those relationships.

I think what we're seeing with products like VerteGlide is some of those accounts that we were doing very little surgery in now, we're now doing a reasonable volume of VerteGlide, which helps our revenue certainly, but probably more importantly, it is exposing those surgeons to the quality of and the clinical relevance of that scoliosis portfolio. We're being taken dramatically more seriously, and we're starting to see pull-through of the RESPONSE Fusion system. I think if you looked at our top 10 growth accounts this year, what you would find is the majority of those accounts are tied out to a great experience they've had with VerteGlide, and now an opportunity to say, Hey, we did this very complex multi-hour surgery that helped a four-year-old with an incredibly complex condition.

I think you deserve the right to come in and do something that's a little simpler. I'll take a look at your RESPONSE Fusion. We're definitely seeing that pull-through. I think VerteGlide's going to be big for us next year. We've got more sets out there finally. We are seeing repeat users from those surgeons. We will continue to host big training events. These are events where 12, 15 surgeons generally come to learn about the system, but also then start to talk to key opinion leaders who are now six months to a year out with some of their first patients and see how those patients are doing. Case in point, this week, the rest of our team is in San Diego at the ICEOS course, which is a big early onset scoliosis course.

We're the largest sponsor of that course. There's a number of labs and a number of panels, discussions where surgeons are talking about early onset scoliosis in the context of VerteGlide. So the momentum is certainly building around that product line.

Rick Wise
Managing Director, Stifel

Another new and novel technology is eLLi, electromechanical growing implant for scoliosis. Are you still on track for IDE approval? I think I had the feeling it's very soon. Do you still expect first cases there to be in early 2027? When would full launch sort of in the same cadence be more like 2028? This seems like another truly new—

Dave Bailey
President and CEO, OrthoPediatrics

Yeah.

Rick Wise
Managing Director, Stifel

—novel, unique technology.

Dave Bailey
President and CEO, OrthoPediatrics

Yeah. eLLi is a big one for us. There's no question. eLLi has a larger market opportunity probably than VerteGlide. VerteGlide is for generally for patients who are very small that have a lot of remaining growth. But sometimes you need to be able to push the spine where the spine is stiffer or the child has less remaining growth. And so eLLi is a mechanical lengthening device. We just run a lab, running a lab this week in San Diego. I think this is going quite well. But we need FDA approval, and so we're waiting on the IDE. We would expect that kind of at any moment here, hopefully early part of the year, and then we'll start doing first cases.

We will be in a debate with FDA associated with what the After we do first cases, how long do we really need to follow these patients before we get a green light? We can't be certain exactly when that full approval will be. But I can say that the interest around eLLi has been, I would say it's massive. I mean, surgeons come all the way to Warsaw, which isn't an easy place to get. Oftentimes, if they're scoliosis surgeons, the number one thing they want to see-

Rick Wise
Managing Director, Stifel

Warsaw, Indiana.

Dave Bailey
President and CEO, OrthoPediatrics

Warsaw, Indiana.

Rick Wise
Managing Director, Stifel

Just in case.

Dave Bailey
President and CEO, OrthoPediatrics

Sorry. Yes. I think they want to see the eLLi device and how it works, and it meets so many unmet needs, and it is a decent-sized market opportunity for us. Again, it drives the usage of RESPONSE Fusion and eventually Veraxis when it is available.

Rick Wise
Managing Director, Stifel

It has been a long time waiting to get to OPSB, Joe. OPSB is going from strength to strength. In the last quarter, I think you are in over 60 clinics, and maybe when I visited Boston Children's Hospital with you.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

A couple years ago.

Rick Wise
Managing Director, Stifel

A couple years ago, you had 30 maybe? And you've doubled in two years. Is this going to be the I mean, I don't know. What's the right number here? 300? 500? I think that's how you told me to phrase the question, Dave.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

Always signing me up for more

Rick Wise
Managing Director, Stifel

Exactly

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

than where we're at. There is a huge runway left. Our goal here was to get within every geography that's within a stone's throw of children's hospitals across the country. If we assume there's about 300 of those, and we're at 60 today, there's 60 clinics today, there's clearly tons of runway to grow. We've been talking a lot about it with target markets, different geographies that we want to do business in. Certain metropolitan areas that have larger population densities and maybe multiple children's hospitals. Strategically, we'll probably go to those sooner than some of the other markets.

Rick Wise
Managing Director, Stifel

Sure.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

But there's a huge runway left for clinics, whether it's greenfield or acquihire. Both of them are appetizing to us. We evaluate it from different sides of the street. Certainly, the acquihires get us into markets faster where we need insurance approvals. And we can acquire those to get into a market and then greenfield beyond those. Also with the acqui-hires, we're able to get through and actually have these maybe be profitable to start, so there's some revenue in there. Different than the greenfields, which start from, you take an investment upfront. Maybe one of the most underappreciated pieces of the OPSB growth has to do with the product growth, not the clinic growth.

Product growth, even when you contrast that to our implant business, doesn't require any set deployment, so from a cash perspective, we don't need to get the inventory like we do traditionally with our implant business. On top of that, the unmet needs on the bracing side is almost where OrthoPediatrics was on the implant side 15 years ago. There is just an unbelievable number of things that need developed. We manage a list. The list gets longer and longer every week.

Rick Wise
Managing Director, Stifel

Wow.

Joe Hauser
President of Trauma and Deformity Correction, OrthoPediatrics

Our job is to try to get those defined into smaller categories, and that's why you see such a huge increase on the OPSB front from a product standpoint, because the ideas are endless. The time to actually get Class one approvals is a little bit more predictable than the Class two devices that we do on the implant side. The regulatory burden is less to maintain those products. The cost of development is less, so you can see why that Super Cycle is one that you're not going to have one product that is going to be an eLLi-type TAM or market opportunity, but you've got a ton of little products that actually can make up a pretty big business from the product side.

Rick Wise
Managing Director, Stifel

30 minutes isn't enough to touch on everything that you're doing, but I feel like I need to touch on profitability. You brought it up several times, Dave. You're balancing Super Cycle growth versus investment and profitability and cash flow, break even or better. I'm sure it's frustrating sometimes that you can't invest more. Are you investing enough? Maybe I should start to ask.

Dave Bailey
President and CEO, OrthoPediatrics

Yeah, it is a challenge. I think we think the prudent approach here is to balance very strong top line revenue growth, but not growth at all costs, which is probably where we were three years ago, particularly when the market was overvaluing probably just pure top line revenue growth. We think a rational, sustainable approach is balancing top line against increasing leverage, EBITDA leverage, and generating free cash. We will not seek over the course of the next few years to maximize positive free cash. As EBITDA goes up, we will be using more of the EBITDA likely in 2027 and 2028 to get more inventory on the street. This year, we're going to deploy $10 million.

We haven't given a guide, but you could assume that we'll take some of the EBITDA from next year's EBITDA growth and probably put more inventory out in 2027 and 2028 to continue to fuel growth. It's a bigger business, so we'll need that. But it isn't to maximize positive free cash flow here. I think what is also misunderstood is that whether we grow by 12%, 15%, or 19%, we don't have someone kind of chasing us down here. We don't have people nipping at our heels. In fact, the competitive landscape is increasingly benign. We will get the growth. I think getting the growth in a measured, rational way, not trying to get it all in one shot and then putting the balance sheet and everything at risk doesn't seem prudent to me, especially when we've built such a dominant competitive position.

Rick Wise
Managing Director, Stifel

Right.

Dave Bailey
President and CEO, OrthoPediatrics

You're likely to see more of the same, I would say, over the course of the next few years.

Rick Wise
Managing Director, Stifel

No, I feel like you've been in a several-year transition as you acquired and integrated, invested in OPSB, and brought all these new products forward, and it feels like you are on a better, more predictable growth tack from here.

Dave Bailey
President and CEO, OrthoPediatrics

I think from an OrthoPediatrics perspective, just to toot our horn here, I think we're a very unique asset in orthopedics. Sub $300 million, getting leveraged on the EBITDA side and generating positive free cash, and still growing the business in the mid-teens. We've seen a lot of companies, particularly the spine assets, that ultimately have to grow much, much larger, have to have much greater scale to be able to generate that kind of Even to get break-even from a free cash flow standpoint. I think it's the strength of a dominant competitive position.

Rick Wise
Managing Director, Stifel

Right.

Dave Bailey
President and CEO, OrthoPediatrics

Very long product life cycles where we can have products out that are still growing 15 years after we launched them, where we're not perpetually having to re-engineer the next new thing to replace a product that we just launched five years ago. Those dynamics make our market quite interesting, and I think it's why we've been able to establish ourselves, I think, as a unique asset in the space.

Rick Wise
Managing Director, Stifel

I was going to ask you about 2027 with Fred not here. Very dangerous. If you're listening, Fred, this is Fred Hite, this is-

Dave Bailey
President and CEO, OrthoPediatrics

My mic just went out. It's weird.

Rick Wise
Managing Director, Stifel

Weird how he probably turned it off remotely. It feels like the business, this is my opinion, is showing impressive sort of stability and accelerating momentum, and it just feels like the setup for the year ahead is really positive. I assume you wouldn't argue with me.

Dave Bailey
President and CEO, OrthoPediatrics

I wouldn't argue. We have a good setup for not just the year ahead, but the next several years ahead.

Rick Wise
Managing Director, Stifel

That's great to hear. On that positive note, we will stop there before I do any more damage. Thank you so much, Stifel out .

Dave Bailey
President and CEO, OrthoPediatrics

Appreciate you.

Rick Wise
Managing Director, Stifel

Thank you.